<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Cyclin D proteins are elevated in many <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e> cells, and targeted deletion of cyclin D1 gene in the mammary tissues protects mice from <z:hpo ids='HP_0003002'>breast cancer</z:hpo> </plain></SENT>
<SENT sid="1" pm="."><plain>Accordingly, there is an increasing awareness of this novel nonenzymatic target for <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e> therapeutics </plain></SENT>
<SENT sid="2" pm="."><plain>We have developed novel, nonalkylating styrylbenzylsulfones that induce cell <z:hpo ids='HP_0011420'>death</z:hpo> in wide variety of <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e> cells without affecting the proliferation and survival of <z:mpath ids='MPATH_458'>normal</z:mpath> cells </plain></SENT>
<SENT sid="3" pm="."><plain>The development of derivatized styrylbenzylsulfones followed logically from a <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> cell cytotoxicity screen performed in our laboratory that did not have an a priori target profile </plain></SENT>
<SENT sid="4" pm="."><plain>Modifications of some of the precursor molecules led to lead optimization with regard to <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> cell cytotoxicity </plain></SENT>
<SENT sid="5" pm="."><plain>In this report we describe the synthesis and structure-activity relationships of novel, nonalkylating (E)-styrylbenzylsulfones and the development of the novel anticancer agent <z:chebi fb="199" ids="26708">sodium</z:chebi> (E)-2-{2-<z:chebi fb="8" ids="32772">methoxy</z:chebi>-5-[(2',4',6'-trimethoxystyrylsulfonyl)<z:chebi fb="36" ids="29309">methyl</z:chebi>]<z:chebi fb="0" ids="48285,48372">phenylamino</z:chebi>}<z:chebi fb="49" ids="30089,47622">acetate</z:chebi> (ON 01910.Na), which is in phase III trials for <z:hpo ids='HP_0002863'>myelodysplastic syndromes</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>) associated with aberrant expression of cyclin D proteins </plain></SENT>
</text></document>